Newsletters

3/13/2019
Imaging3 Signs Letter of Intent for Reverse Acquisition by CA Cannabis Company
12/6/2018
Imaging3 Provides Year-End Corporate Update
4/30/2018
Imaging3 Announces Appointment of George Zdasiuk to Board of Directors
3/15/2018
Imaging3 Announces 1-20 Reverse Stock Split
2/16/2018
Newly Appointed CEO John Hollister Reflects on his First 45 Days at The Company
12/20/2017
Imaging3 appoints John Hollister as CEO
9/29/2017
Imaging3 Announces Filing of Proxy Statement
8/1/2017
Imaging3 Announces Successful Conclusion of Mandatory Self-Remediation Period
7/31/2017
Imaging3 Announces Successful Conclusion of Mandatory Self-Remediation Period
6/20/2017
Imaging3 Engages Intertek to Assist with Hazard Analytic Requirements Relating to the 510(k) Application with the FDA
6/12/2017
Imaging3 Engages Med-Device Consulting, Inc. to Assist on 510(k) Application with the FDA
2/10/2017
Imaging3 Clarifies Announcement Concerning Closing of the Company’s Bankruptcy Proceeding
2/10/2017
Imaging3 Clarifies Announcement Concerning Closing of the Company’s Bankruptcy Proceeding
2/7/2017
Imaging3 Announces Closing of the Company’s Bankruptcy Proceeding
1/30/2017
Imaging3 and Greenberg Glusker Reach Agreement on Legal Fees
11/29/2016
Scott R. Pancoast Joins the Imaging3 Team
10/12/2016
Imaging3, Inc. (OTCQB: “IGNG”) Announces Execution of Consulting Service Agreement with Biologics Consulting Group, Inc.
9/14/2016
Imaging3, Inc. (OTCQB: “IGNG”) Announces execution of agreement with CriTech Research to Complete Software Verification, Validation and Remediation for the Company’s Planned FDA 510(k) Application
9/7/2016
Imaging3, Inc. Announces Commencement of Trading of its Common Stock on the OTCQB under Trading Symbol “IGNG”.
7/14/2016
Imaging3, Inc. announces it is now approved for trading.